Targeting Pathological Hyperinsulinemia in Genetically Burdened Normoglycemic Offspring: A Proposed Clinical Risk Matrix and Cytoprotective Framework

Traditional diagnostic criteria for Type 2 Diabetes Mellitus (T2DM)—anchored rigidly in fasting plasma glucose (FPG ≥ 126 mg/dL) and glycated hemoglobin (HbA1c ≥ 6.5%) thresholds—are inherently reactive, acting as lagging indicators of metabolic collapse. Landmark autopsy and epidemiological data reveal an irreversible depletion of 50% to 70% of functional β-cell mass by the time clinical hyperglycemia manifests. Focusing exclusively on an ultra-high-risk population—offspring with a profound genetic burden—this perspective challenges the prevailing dogma that views early hyperinsulinemia merely as a benign compensatory phase. Instead, we conceptualize Pathological Chronic Hyperinsulinemia as an active cytotoxic and vasotoxic driver, inflicting silent, multi-organ damage via Unfolded Protein Response (UPR) failure and autophagy collapse. To strictly mitigate overdiagnosis and excessive medicalization, we propose a heuristic, hyperinsulinemia-centered pre-diagnostic risk matrix. This framework utilizes familial pedigree as a non-negotiable inclusion gatekeeper, integrated with high-fidelity markers such as the globally accessible Triglyceride-Glucose (TyG) index and the fasting Proinsulin-to-C-peptide ratio—meticulously adjusted to exclude non-metabolic confounders. Crucially, for normoglycemic offspring crossing the proposed clinical threshold (score ≥ 5.5), we outline a mechanistic rationale for a shift toward early Pharmacological Shielding. Utilizing Metformin (initiated at a low, tolerability-adjusted dose) as an emergency cytoprotective adjunct to intensive lifestyle modifications, this proposed paradigm leverages mTORC1-mediated autophagy to restore PC1/3 processing enzymes, prevents FoxO1-depleted dedifferentiation, induces β-cell rest, and modulates the Akkermansia muciniphila-driven incretin axis. Ultimately, this framework provides a theoretical and clinical basis for future trials aimed at fundamentally unloading the biosynthetic burden on β-cells, preserving the endogenous insulin source, and mitigating lifelong systemic complications